Table 2.
Percentage of cells expressing, or MFI of isolated neutrophil cell surface markers measured by flow cytometry in AMC (n = 26), COVID-19 patients (n = 34) or CAP patients (n = 16). Data displayed as median (IQR). Data analyzed by individual one way ANOVA with multiple comparisons. Bold indicates significance where * vs. AMC, # vs. COVID-19 and $ vs. CAP.
| Receptors | % Expression | MFI | ||||||
|---|---|---|---|---|---|---|---|---|
| AMC n = 26 |
COVID n = 34 |
CAP n = 16 |
p Value | AMC n = 26 |
COVID n = 34 |
CAP n = 16 |
p Value | |
| CD10 | 94.3 (11.52) | 95.3 (13.6) | 74.7 *# (60.6) |
* <0.0006 # <0.0006 |
669 (511) |
836 (518) |
701 (486) |
0.304 |
| CD11b | 81.6 (15.25) |
67.8 *$ (43.9) |
83.9 (23.8) |
* 0.0014 $ 0.046 |
399 (331) |
40 *$ (223) |
1701 * (1268) |
* 0.0026 $ <0.0001 * <0.0001 |
| CD54 | 26.2 (37.0) | 71.3 *$ (21.2) |
6.6 (10.9) |
* <0.0001 $ <0.0001 |
33 (48) |
73 (58) |
147 *# (77) |
* 0.0001 # 0.0012 |
| CD62L | 23.3 (58.8) | 31.0 (15.3) | 49.9 (41.4) |
0.384 | 68 (400) |
94 (121) |
723 *# (519) |
* 0.0005 # <0.0001 |
| CXCR2 | 99.9 (0.1) | 100 (0.2) | 98.5 (1.6) |
0.741 | 2482 (1415) | 2031 (1600) | 2839 (2839) |
0.439 |
| CXCR4 | 93.9 (16.4) |
96.7 (9.07) | 54.3 *# (35.0) |
* <0.0001 # <0.0001 |
1917 (4039) |
1724$ (4177) |
1090 (1376) |
$ 0.028 |
| CD66b | 99.7 (0.5) | 99.8 (0.3) | 97.6 (1.6) |
0.298 | 324 (367) |
186 (161) |
1631 *# (1493) |
* <0.0001 # <0.0001 |
| CD11c | 99.2 (2.9) |
99.9 (1.05) | 76.1 *# (64.5) |
* <0.0065 # <0.0001 |
392 (2120) |
1148 (670) | 4197 *# (6040) |
* <0.0001 # <0.0001 |
| PD-L1 | 63.8 (32) |
98 (27.9) | 8.7 *# (12.9) |
* <0.0001 # <0.0001 |
193 (210) |
70 *$ (132) |
524 * (264) |
* 0.006 $ <0.0001 * 0.0006 |